Q4 2025 Earnings Call February 26, 2026 8:30 AM ESTCompany ParticipantsLuis Sanay - Vice President of Investor RelationsJohn Jacobs ...

Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.

Novavax has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties.

Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed ...

Dozens of Guam's teachers, school administrators and Guam Police Department officers underwent five days of intensive ...

Paramount Chief David Ellison, who began his pursuit of Warner Bros. last fall, said he was pleased Warner's board ...

The resulting outcome is that you have A.I. systems that have learned what it means to solve a problem that takes quite a ...

Sanofi is leading commercialization efforts for Nuvaxovid and Novavax is eligible to receive ongoing tiered royalties from sales of the vaccine. A full 12-month commercial cycle under Sanofi’s control ...

ESPN is thinking strategically about college basketball as the sport seeks attention and eyeballs within an increasingly competitive marketplace.

Critical reinforcement materials will enhance initiatives for IC substrates and semiconductor packaging technologies.

FibreCoat and partners Coleitec and Forward Engineering display an HP-RTM-processed prototype that successfully validates ...

The messaging app’s founder has become a poster boy for the backlash in Europe over CEO accountability — and a target for ...